Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of ISIS 301012 dosing in hypercholesterolemic subjects
2004-003934-32Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing ISIS 301012 dosing regimens with Placebo (2 arms). Primary endpoints: Safety and tolerability of ISIS 301012 loading and maintenance regimens, Pharmacokinetics of ISIS 301012 and 1 more. Started Jan 2005; status: completed.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2004-003934-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003934-32.